MENU

EXEL Stock Exelixis (EXEL, $38.31) Moving Average Convergence Divergence (MACD) Histogram turned positive on August 15, 2025

A.I.dvisor
at Tickeron.com
Loading...
EXEL - Exelixis
MACD signal
Bullish Trend
Odds of UP Trend
Tickeron
MACD signal
Price: $38.31
Daily change: -$0.16 (-0.42%)
Daily volume: 2.4M
Capitalization: $10.3B
Industry: Biotechnology
This is a Bullish indicator signaling EXEL's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 45 similar cases where EXEL's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:

Momentum Indicator for EXEL turns positive, indicating new upward trend

EXEL saw its Momentum Indicator move above the 0 level on August 12, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where EXEL's RSI Indicator exited the oversold zone, of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for EXEL just turned positive on August 15, 2025. Looking at past instances where EXEL's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EXEL advanced for three days, in of 310 cases, the price rose further within the following month. The odds of a continued upward trend are .

EXEL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 69 cases where EXEL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

EXEL moved below its 50-day moving average on July 29, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for EXEL crossed bearishly below the 50-day moving average on July 30, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXEL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for EXEL entered a downward trend on August 08, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. EXEL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.968) is normal, around the industry mean (19.363). P/E Ratio (18.038) is within average values for comparable stocks, (50.340). Projected Growth (PEG Ratio) (2.618) is also within normal values, averaging (2.941). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (4.869) is also within normal values, averaging (299.736).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. EXEL showed earnings on July 28, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a developer of small molecule therapies for the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
1851 Harbor Bay Parkway
Phone
+1 650 837-7000
Employees
1310
Web
https://www.exelixis.com